Table 3.
Mutation analyses for BRAF, KRAS, PI3K3CA within different subgroups. (a) Mutation frequency for BRAF, KRAS, PI3K3CA. (b) P-values (Fisher exact test) for group comparisons.
| A) | |||
|---|---|---|---|
| Entity | BRAF | KRAS | PI3K3CA |
| HP (9) | 0% | 0% | 11% |
| Small adenoma (LGD) (10) | 0% | 20% | 10% |
| Large adenoma (LGD) (11) | 9% | 27% | 18% |
| Adenoma with HGD (9) | 0% | 11% | 44% |
| SSA/P (23) | 4% | 0% | 0% |
| TSA (7) | 14% | 14% | 0% |
| MSI-L CRC(9) | 0% | 0% | 0% |
| MSI-H CRC (18) | 0% | 6% | 18% |
| SUM (96) | |||
| B) | |||
|---|---|---|---|
| Entity | p-value | p-value | p-value |
| BRAF | PI3K3CA | KRAS | |
| SSA/P vs. TSA | 0.42 | 1.00 | 0.24 |
| Large adenoma vs. small adenoma | 1.00 | 1.00 | 1.00 |
| Adenoma (LGD) vs. adenoma (HGD) | 1.00 | 0.15 | 0.64 |
| SSA/P + TSA vs. small adenoma | 1.00 | 0.25 | 0.15 |
| SSA/P + TSA vs. MSI-H CRC | 0.52 | 0.047 | 1.00 |
| SSA/P vs. MSI-H CRC | 1.00 | 0.07 | 0.44 |
| TSA vs. MSI-H CRC | 0.28 | 0.53 | 0.49 |
Abbreviations: HP, hyperplastic polyps; LGD, low grade dysplasia; HGD, high grade dysplasia; SSA/P, sessile serrated adenoma/polyp; TSA, traditional serrated adenoma; CRC colorectal cancer; MSI-H, high microsatellite instable; MSI-L, low microsatellite instable.